EU advises adding condition to AstraZeneca label
The vaccine has been linked to rare blood clots in the past, but health officials say its benefits always outweigh the small risks.
the experts also concluded that the condition of capillary leakage should be added to the product information as a new side effect of the vaccine.
The agency said it is continuing to examine heart inflammation in a small number of people who have developed conditions after being immunized with vaccines made by Pfizer-BioNTech or Moderna Inc.
The EMA said it was studying cases of myocarditis, inflammation of the heart and pericarditis, an inflammation of the membrane surrounding the heart. Symptoms include shortness of breath and chest pain; the problems are usually temporary.
“Further analysis is needed to determine whether there is a causal link with vaccines,” the European agency said.
The EMA said it plans to finalize its review of these cases next month.